段炼. 烟雾病诊断、治疗及发病原因的思考[J]. 中国卒中杂志, 2008, 7:470-471.Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan[J]. Clin Neurol Neurosurg, 1997, 99:S238-S240.Yamauchi T, Tada M, Houkin K, et al. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25[J]. Stroke, 2000, 31:930-935.No authors listed. National Institutes of Health Consensus Development Conference statement:neurofibromatosis[J]. Neurofibromatosis. 1988, 1:172-178.中华神经科学会. 各类脑血管疾病诊断要点[J]. 中华神经科杂志, 1996, 29:379-380.Koc F, Yerdelen D, Koc Z. Neurofibromatosis type 1 association with moyamoya disease[J]. Int J Neurosci, 2008, 118:1157-1163.Darrigo Júnior LG, Valera ET, Machado Ade A, et al. Moyamoya syndrome associated with neurofibromatosis type I in a pediatric patient[J]. Sao Paulo Med J, 2011, 129:110-112.Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1[J]. Neurology, 2005, 64:553-555.Rea D, Brandsema JF, Armstrong D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1[J]. Pediatrics, 2009, 124:e476-e483.Ghosh PS, Rothner AD, Emch TM, et al. Cerebral vasculopathy in children with neurofibromatosis type 1[J]. J Child Neurol, 2013, 28:95-101.Li F, Munchhof AM, White HA, et al. Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells[J]. Hum Mol Genet, 2006, 15:1921-1930.Hamilton SJ, Friedman JM. Insights into the pathogenesis of neurofibromatosis 1 vasculopathy[J]. Clin Genet, 2000, 58:341-344. |